Across TCGA pan-cancer cohorts, SIRPA Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SIRPA data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SIRPA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIRPA expression acts as an unfavorable survival marker.

HNSC, BLCA, and SKCM are the cancer types where SIRPA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.138	0.751	<.001	48	view →
BLCA	DFS	Median	III,IV	0.078	0.489	<.001	9	view →
SKCM	DFS	Median	All	0.063	0.757	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SIRPA tumor-vs-normal RNA expression · all SIRPA data types